Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 14/20 | 0.45 |
| ▸ | RBP4 | P02753 | 6/20 | 0.44 |
| ▸ | MC5R | P33032 | 4/20 | 0.43 |
| ▸ | MC3R | P41968 | 4/20 | 0.43 |
| ▸ | MC1R | Q01726 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698209 | 0.86 | MC4R (0.47) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL4678746 | 0.85 | TACR1 (0.48) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL4697626 | 0.85 | MC4R (0.46) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL4675958 | 0.84 | MC4R (0.44) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL4698368 | 0.84 | MC4R (0.45) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL4698090 | 0.84 | MC4R (0.44) | MC4RMC5RMC3RMC1RCYP3A4 | |
| SCHEMBL6321032 | 0.83 | MC4R (0.42) | MC4RRBP4MC5RMC3RMC1R | |
| SCHEMBL4700096 | 0.83 | MC4R (0.57) | MC4RMC5RMC3RMC1R | |
| SCHEMBL4515132 | 0.82 | MC4R (0.52) | MC4RMC3R | |
| SCHEMBL4698459 | 0.81 | MC4R (0.48) | MC4RMC5RMC3RMC1RCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | claimed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | claimed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | claimed |
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | MC4R 1/4885RBP4 1528/4885MC5R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.